

Invitation to Workshop, 4th of December, Hotel Admiral, Copenhagen, Denmark

Inno-HTA: Adding value to comprehensive early assessment of health care innovations from a public and private perspective

New pharmaceuticals, medical devices, and interventional procedures provide a promise to patients and consumers of improved health care, and there is a pressure on regulatory agencies to get them out to patients as soon as possible, but secure their safety and efficacy. The industry developing these health care innovations need to anticipate requirements for later evidence-based assessment already in an early stage, and internally assess the likely performance of the new technology during all stages of development and testing. Early health technology assessment is therefore an essential support to both decision-making in the public and the private domain.

The EU-funded project *HTA-Methodology for Innovative Healthcare Technologies (Inno-HTA)* (www.inno-hta.eu) set out to identify potential gaps between the development of new technologies and their application. This was done by applying an innovation systems approach to early assessment, by scrutinizing existing approaches to early assessment, and by means of soliciting the various stakeholders involved. The Inno-HTA project has identified evidence-gaps and makes suggestions for the inclusion of several new indicators in early assessment from both public and private stakeholders groups' perspectives (regulators, payers, providers, HTA researchers, patients/consumers, industry).

The Inno-HTA consortium would like to discuss the results of the project with you in a multi-stakeholder setting. To stimulate the debate we have organized a one-day workshop with exciting speakers representing the various interest groups (please find the programme attached).

The goal of the workshop is to recommend a set of indicators for early assessment of new health technologies.

Participation to the workshop is free, but restricted to 30 people. We will apply the first-come-first serve principle.

Key information:

Date and Place: Workshop 4th of December, 2008, Hotel Admiral, Copenhagen, Denmark (www.admiralhotel.dk)

Organising agency: Danish Centre for Health Technology Assessment (DACEHTA), National Board of Health, Copenhagen, Denmark.

Registration: By e-mail to Karin Holm Andersen: KAN@SST.DK . Please write 'Registration Inno-HTA' in the subject field. Deadline for registration: **26th of November, 2008.**

Programme Inno-HTA Workshop 4th of December 2008, Hotel Admiral, Copenhagen

Chairperson: Rosanna Tarricone, PhD, Director Economic Affairs Department, Eucomed

- 9- 9.15 **Workshop opening - Finn Børlum Kristensen.** National Board of Health, Project leader European Network for HTA – EunetHTA, Adjunct Professor, University of Southern Denmark.
- 9.15-10.00 **Key note address - Arie Rip.** Professor of Philosophy of Science and Technology in the School of Management and Governance of the University of Twente, The Netherlands. **Constructive assessment of emerging technologies: bridging the gap between innovation and regulation.**
- 10.00-10.45 **Results of Inno-HTA - Bernhard Buehrlen,** Coordinator Inno-HTA project, Fraunhofer Institute.
- 11.00-11.30 *Coffee and tea break*
- 11.30-12.15 **HTA perspective - Kristian Lampe,** Senior Medical Officer, FinOHTA, project leader of EunetHTA WP4 on developing a core model for HTA
Added value of Inno-HTA in relation to ‘classic’ HTA
- 12.15-13.00 **Industry perspective - Richard Bergström,** Vice-chair of EFPIA’s (The European Federation of Pharmaceutical Industries and Associations) HTA Working Group, Director-General of LIF, The Swedish Association of the Pharmaceutical Industry. **Added value of Inno-HTA for producers/manufacturers’ R&D decision-making.**
- 12.30-13.00 Discussion
- 13.00-14.00 *Lunch break*
- 14.00-14.45 **Patient/Consumer perspective - Cees Smit,** The Dutch Genetic Alliance (VSOP), Honorary member of Epposi, The European Platform for Patients’ Organisations, Science and Industry.
Added value of Inno-HTA for consumers/patients
- 14.45-15.30 **Regulatory perspective – Fabian Waechter,** Austrian Agency for Health and Food Safety (AGES)
Added value of Inno-HTA to support national and European R&D policy
- 15.30-16.00 *Coffee and tea break*
- 16.00-16.45 **Never too early to evaluate?**
Panel discussion about the pros and cons of, and conditions for early evaluation with **Iñaki Gutiérrez Ibarluzea**, chairman of EuroScan, **Arie Rip**, and the speakers (representatives of the different perspectives).
- 16.45-17.00 Next steps – closure by chairperson